US FDA accepts lurasidone filing for schizophrenia
This article was originally published in Scrip
The US FDA has accepted for standard review Dainippon Sumitomo Pharma's (DSP) NDA for the atypical antipsychotic lurasidone, for the treatment of acute schizophrenia.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.